Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Ascendis Pharma A (ASND) over the last 14 years, with Q4 2025 value amounting to $1.7 billion.

  • Ascendis Pharma A's Total Liabilities rose 2421.61% to $1.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.7 billion, marking a year-over-year increase of 2421.61%. This contributed to the annual value of $1.7 billion for FY2025, which is 2058.32% up from last year.
  • Ascendis Pharma A's Total Liabilities amounted to $1.7 billion in Q4 2025, which was up 2421.61% from $1.6 billion recorded in Q3 2025.
  • In the past 5 years, Ascendis Pharma A's Total Liabilities ranged from a high of $1.7 billion in Q4 2025 and a low of $196.0 million during Q1 2021
  • In the last 5 years, Ascendis Pharma A's Total Liabilities had a median value of $944.1 million in 2023 and averaged $942.8 million.
  • Per our database at Business Quant, Ascendis Pharma A's Total Liabilities skyrocketed by 30336.13% in 2022 and then surged by 772.57% in 2023.
  • Ascendis Pharma A's Total Liabilities (Quarter) stood at $230.3 million in 2021, then skyrocketed by 266.15% to $843.1 million in 2022, then grew by 23.95% to $1.0 billion in 2023, then soared by 31.42% to $1.4 billion in 2024, then rose by 24.22% to $1.7 billion in 2025.
  • Its Total Liabilities stands at $1.7 billion for Q4 2025, versus $1.6 billion for Q3 2025 and $1.4 billion for Q2 2025.